Core Insights - Allergan Aesthetics, a subsidiary of AbbVie, is showcasing its leadership in the aesthetic industry by presenting 17 abstracts at the 2025 American Society of Dermatologic Surgery (ASDS) Annual Meeting, including three in the "Top Ten" session [1][2] - The presentations will cover Phase 3 clinical study results for trenibotulinumtoxinE, a first-in-class botulinum neurotoxin, and a Phase 4 study on BOTOX® Cosmetic, focusing on patient satisfaction and natural outcomes [1][3] - The company emphasizes its commitment to evidence-based innovation and improving patient care through its diverse product portfolio [2] Presentation Highlights - Key presentations include the efficacy and safety of trenibotulinumtoxinE for treating glabellar lines, and patient-reported satisfaction following BOTOX® Cosmetic treatment for upper facial lines [4][5] - An expert panel will discuss insights from the "Hyaluronic Acid Injectable Fillers Report," focusing on current usage and satisfaction data for hyaluronic acid fillers [4] - A symposium will address the latest indications for BOTOX® Cosmetic, including treatment for moderate to severe platysma bands [4] Educational Initiatives - Allergan Aesthetics will host educational programs aimed at understanding patient needs and enhancing clinical practices [3] - Presentations will also cover the benefits of long-term BOTOX® Cosmetic use and survey results on aesthetic concerns following medical weight loss [3][4] Company Overview - Allergan Aesthetics develops and markets a wide range of aesthetic products, including facial injectables and body contouring solutions, with a focus on innovation and customer service [30] - AbbVie aims to address serious health issues through innovative medicines, with a significant presence in the aesthetics market [31]

Core Viewpoint - Allergan Aesthetics, a subsidiary of AbbVie, has launched the HA5® Hydra Collagen Hydrating Foaming Cleanser, which is designed to provide hydration and thorough cleansing for the skin, enhancing the effectiveness of subsequent skincare products [1][2]. Product Overview - The HA5® Hydra Collagen Hydrating Foaming Cleanser features the proprietary HA5® Hydra Collagen Complex, which includes five forms of hyaluronic acid and vegan hydra collagen, aimed at delivering instant hydration [1][2]. - The cleanser is formulated with 100% naturally derived amino acid-based surfactants and Pea Peptides, making it suitable for dry and sensitive skin [2]. - Clinical studies indicate that the cleanser can effectively remove makeup and impurities while boosting skin hydration by 30% when used with the HA5® Hydra Collagen Replenish + Restore Hydrator [2][3]. Market Positioning - Allergan Aesthetics emphasizes innovation in aesthetic medicine, positioning the HA5® line as a benchmark for advanced skin hydration solutions [2]. - The new cleanser is part of a broader portfolio that includes products from SkinMedica®, SKINVIVE by JUVÉDERM®, and DiamondGlow®, all aimed at providing superior hydration [2]. Expert Endorsement - Dr. Tiffany J. Libby, a board-certified dermatologist, endorses the product, highlighting its dual function of cleansing and hydrating while respecting the skin barrier [3]. Pricing and Availability - The HA5® Hydra Collagen Hydrating Foaming Cleanser is priced at $48 and is available for purchase on SkinMedica.com [3].

Core Viewpoint - Allergan Aesthetics, a subsidiary of AbbVie, has submitted a supplemental premarket approval application for SKINVIVE by JUVÉDERM® to reduce neck lines, which is currently approved for improving cheek skin smoothness in adults over 21 [1][7]. Group 1: Product Development and Market Potential - SKINVIVE by JUVÉDERM® is an injectable hyaluronic acid product aimed at improving neck appearance, addressing a significant concern for many consumers seeking aesthetic treatments [2][4]. - The product could become the first hyaluronic acid injectable specifically targeting neck lines, expanding Allergan's portfolio which includes BOTOX Cosmetic® and SkinMedica® [2][7]. - The submission is backed by a clinical study showing that 80% of patients achieved at least a 1-grade improvement in neck lines after one month of treatment [3]. Group 2: Clinical Study Results - The clinical study met all primary and secondary endpoints, with nearly 90% of patients reporting improvement in neck appearance as assessed by the Global Aesthetic Improvement Scale [3]. - Patients reported being significantly less bothered by their neck appearance post-treatment, while the control group showed no significant change [3]. - Adverse events associated with SKINVIVE by JUVÉDERM® were mild and consistent with its known safety profile, indicating a favorable safety outcome for the product [3]. Group 3: Company Background and Strategy - Allergan Aesthetics focuses on developing innovative aesthetic solutions, with a commitment to addressing consumer needs in the aesthetics market [36]. - AbbVie aims to deliver innovative medicines and solutions across various therapeutic areas, including aesthetics, highlighting its strategic focus on addressing health issues and enhancing quality of life [37].